TRVI · Trevi Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| BASKETT FOREST 10% Owner | ▲ Buy | Open Market | 10,421,428 Shares held | 4/11/2022 | View profile |
| New Enterprise Associates 16, L.P. 10% Owner | ▲ Buy | Open Market | 10,421,428 Shares held | 4/11/2022 | View profile |
| TPG GP A, LLC 10% Owner | ▼ Sell | Open Market | 3,824,883 Shares held | 7/5/2022 | View profile |
| Ali Behbahani Director | ▲ Buy | Open Market | 948,948 Shares held | 4/11/2022 | View profile |
| Scott D. Sandell 10% Owner | ▲ Buy | Open Market | 948,948 Shares held | 4/11/2022 | View profile |
| Carmen Chang 10% Owner | ▲ Buy | Open Market | 948,948 Shares held | 4/11/2022 | View profile |
| Edward T. Mathers Director | ▲ Buy | Grant | 948,948 Shares held | 4/11/2022 | View profile |
| Sonsini Peter W. 10% Owner | ▲ Buy | Open Market | 948,948 Shares held | 4/11/2022 | View profile |
| Makhzoumi Mohamad 10% Owner | ▲ Buy | Open Market | 948,948 Shares held | 4/11/2022 | View profile |
| Florence Anthony A. Jr. 10% Owner | ▲ Buy | Open Market | 948,948 Shares held | 4/11/2022 | View profile |
| Walker Paul Edward 10% Owner | ▲ Buy | Open Market | 948,948 Shares held | 4/11/2022 | View profile |
| David P. Meeker President and CEO | ▼ Sell | Open Market | 352,489 Shares held | 8/27/2024 | View profile |
| SCIASCIA THOMAS Chief Scientific Officer | ▼ Sell | Open Market | 221,373 Shares held | 3/25/2025 | View profile |
| Jennifer L. Good Director | ▼ Sell | Open Market | 213,313 Shares held | 3/21/2025 | View profile |
| Simon Farrell Chief Commercial Officer | ▼ Sell | Open Market | 76,900 Shares held | 3/10/2025 | View profile |
| Delfini Lisa Chief Financial Officer | ▲ Buy | Option Exercise | 64,660 Shares held | 1/8/2025 | View profile |
| Galletta Christopher See Remarks | ▲ Buy | Option Exercise | 26,095 Shares held | 12/2/2025 | View profile |
| Heffernan Michael Thomas Director | ▼ Sell | Open Market | 6,351 Shares held | 9/15/2026 | View profile |
Transaction History
| Heffernan Michael Thomas | ▲ Buy | Option Exercise | 18,421 | $56K | 9/15/2026 |
| Heffernan Michael Thomas | ▼ Sell | Open Market | 18,321 | $276K | 9/15/2026 |
| Heffernan Michael Thomas | ▼ Sell | Open Market | 100 | $2K | 9/15/2026 |
| Heffernan Michael Thomas | ▲ Buy | Option Exercise | 21,052 | $70K | 9/15/2026 |
| Heffernan Michael Thomas | ▼ Sell | Open Market | 20,952 | $316K | 9/15/2026 |
| Heffernan Michael Thomas | ▼ Sell | Open Market | 100 | $2K | 9/15/2026 |
| Galletta Christopher | ▲ Buy | Option Exercise | 4,225 | $2K | 12/2/2025 |
| SCIASCIA THOMAS | ▲ Buy | Option Exercise | 2,631 | $4K | 3/25/2025 |
| SCIASCIA THOMAS | ▼ Sell | Open Market | 2,631 | $17K | 3/25/2025 |
| Jennifer L. Good | ▲ Buy | Option Exercise | 5,263 | $8K | 3/21/2025 |
| Jennifer L. Good | ▼ Sell | Open Market | 5,263 | $35K | 3/21/2025 |
| Simon Farrell | ▲ Buy | Option Exercise | 63,813 | $250K | 3/10/2025 |
| Simon Farrell | ▲ Buy | Option Exercise | 31,250 | $16K | 3/10/2025 |
| Simon Farrell | ▼ Sell | Open Market | 4,350 | $31K | 3/10/2025 |
| Simon Farrell | ▼ Sell | Open Market | 76,963 | $518K | 3/10/2025 |
| Simon Farrell | ▲ Buy | Option Exercise | 17,500 | $56K | 3/10/2025 |
| Delfini Lisa | ▲ Buy | Option Exercise | 5,000 | $3K | 1/8/2025 |
| Delfini Lisa | ▲ Buy | Option Exercise | 1,000 | $511 | 1/7/2025 |
| Galletta Christopher | ▲ Buy | Option Exercise | 15,000 | $8K | 12/13/2024 |
| Jennifer L. Good | ▲ Buy | Option Exercise | 1,840 | $3K | 9/9/2024 |
| Jennifer L. Good | ▼ Sell | Open Market | 1,840 | $6K | 9/9/2024 |
| Jennifer L. Good | ▲ Buy | Option Exercise | 4,219 | $6K | 9/6/2024 |
| Jennifer L. Good | ▼ Sell | Open Market | 4,219 | $13K | 9/6/2024 |
| Jennifer L. Good | ▲ Buy | Option Exercise | 40,277 | $58K | 9/5/2024 |
| Jennifer L. Good | ▼ Sell | Open Market | 40,277 | $125K | 9/5/2024 |
| Jennifer L. Good | ▲ Buy | Option Exercise | 10,981 | $16K | 9/4/2024 |
| Jennifer L. Good | ▼ Sell | Open Market | 10,981 | $33K | 9/4/2024 |
| Jennifer L. Good | ▲ Buy | Option Exercise | 3,863 | $6K | 9/3/2024 |
| Jennifer L. Good | ▼ Sell | Open Market | 3,863 | $12K | 9/3/2024 |
| David P. Meeker | ▲ Buy | Option Exercise | 4,555 | $7K | 8/27/2024 |
| David P. Meeker | ▼ Sell | Open Market | 4,555 | $13K | 8/27/2024 |
| SCIASCIA THOMAS | ▲ Buy | Option Exercise | 16,496 | $24K | 8/19/2024 |
| SCIASCIA THOMAS | ▼ Sell | Open Market | 16,496 | $49K | 8/19/2024 |
| SCIASCIA THOMAS | ▲ Buy | Option Exercise | 18,660 | $27K | 8/16/2024 |
| SCIASCIA THOMAS | ▼ Sell | Open Market | 18,660 | $51K | 8/16/2024 |
| SCIASCIA THOMAS | ▲ Buy | Option Exercise | 12,745 | $18K | 8/15/2024 |
| SCIASCIA THOMAS | ▼ Sell | Open Market | 12,745 | $36K | 8/15/2024 |
| SCIASCIA THOMAS | ▲ Buy | Option Exercise | 100 | $143 | 8/14/2024 |
| SCIASCIA THOMAS | ▼ Sell | Open Market | 100 | $275 | 8/14/2024 |
| SCIASCIA THOMAS | ▲ Buy | Option Exercise | 59,354 | $130K | 5/29/2024 |
| SCIASCIA THOMAS | ▼ Sell | Open Market | 53,368 | $136K | 5/29/2024 |
| Delfini Lisa | ▼ Sell | Open Market | 4,350 | $11K | 5/22/2024 |
| Delfini Lisa | ▲ Buy | Option Exercise | 16,043 | $8K | 5/22/2024 |
| Jennifer L. Good | ▲ Buy | Option Exercise | 25,037 | $55K | 5/20/2024 |
| Jennifer L. Good | ▼ Sell | Open Market | 25,037 | $72K | 5/20/2024 |
| Jennifer L. Good | ▲ Buy | Option Exercise | 4,578 | $10K | 5/10/2024 |
| Jennifer L. Good | ▼ Sell | Open Market | 4,578 | $13K | 5/10/2024 |
| Delfini Lisa | ▲ Buy | Option Exercise | 2,292 | $1K | 10/11/2023 |
| Delfini Lisa | ▼ Sell | Open Market | 785 | $2K | 10/11/2023 |
| Delfini Lisa | ▲ Buy | Option Exercise | 2,291 | $1K | 9/11/2023 |
| Delfini Lisa | ▼ Sell | Open Market | 711 | $2K | 9/11/2023 |
| Delfini Lisa | ▲ Buy | Option Exercise | 2,292 | $1K | 8/11/2023 |
| Delfini Lisa | ▼ Sell | Open Market | 682 | $2K | 8/11/2023 |
| Delfini Lisa | ▼ Sell | Open Market | 687 | $2K | 7/11/2023 |
| Delfini Lisa | ▲ Buy | Option Exercise | 2,292 | $1K | 7/11/2023 |
| Simon Farrell | ▲ Buy | Option Exercise | 6,250 | $3K | 6/20/2023 |
| Delfini Lisa | ▲ Buy | Option Exercise | 2,291 | $1K | 6/12/2023 |
| Delfini Lisa | ▼ Sell | Open Market | 610 | $2K | 6/12/2023 |
| Delfini Lisa | ▲ Buy | Option Exercise | 2,291 | $1K | 5/11/2023 |
| Delfini Lisa | ▼ Sell | Open Market | 562 | $2K | 5/11/2023 |
| Delfini Lisa | ▲ Buy | Option Exercise | 2,292 | $1K | 4/11/2023 |
| Delfini Lisa | ▼ Sell | Open Market | 840 | $2K | 4/11/2023 |
| Delfini Lisa | ▲ Buy | Option Exercise | 2,291 | $1K | 3/13/2023 |
| Delfini Lisa | ▼ Sell | Open Market | 892 | $2K | 3/13/2023 |
| Simon Farrell | ▲ Buy | Option Exercise | 18,750 | $10K | 3/7/2023 |
| Delfini Lisa | ▲ Buy | Option Exercise | 27,500 | $14K | 2/13/2023 |
| Delfini Lisa | ▼ Sell | Open Market | 8,474 | $21K | 2/13/2023 |
| TPG GP A, LLC | ▼ Sell | Open Market | 63,569 | $198K | 7/5/2022 |
| TPG GP A, LLC | ▼ Sell | Open Market | 436,431 | $1.2M | 7/1/2022 |
| TPG GP A, LLC | ▼ Sell | Open Market | 429,838 | $1.2M | 6/30/2022 |
| TPG GP A, LLC | ▼ Sell | Open Market | 46,128 | $126K | 6/29/2022 |
| TPG GP A, LLC | ▼ Sell | Open Market | 600 | $2K | 5/2/2022 |
| TPG GP A, LLC | ▼ Sell | Open Market | 16,163 | $44K | 4/29/2022 |
| TPG GP A, LLC | ▼ Sell | Open Market | 7,271 | $20K | 4/28/2022 |
| Sonsini Peter W. | ▲ Buy | Open Market | 2,631,578 | $5.0M | 4/11/2022 |
| Scott D. Sandell | ▲ Buy | Open Market | 2,631,578 | $5.0M | 4/11/2022 |
| Florence Anthony A. Jr. | ▲ Buy | Open Market | 2,631,578 | $5.0M | 4/11/2022 |
| Carmen Chang | ▲ Buy | Open Market | 2,631,578 | $5.0M | 4/11/2022 |
| Ali Behbahani | ▲ Buy | Open Market | 948,948 | $1.8M | 4/11/2022 |
| Florence Anthony A. Jr. | ▲ Buy | Open Market | 948,948 | $1.8M | 4/11/2022 |
| Walker Paul Edward | ▲ Buy | Open Market | 2,631,578 | $5.0M | 4/11/2022 |
| Scott D. Sandell | ▲ Buy | Open Market | 948,948 | $1.8M | 4/11/2022 |
| Carmen Chang | ▲ Buy | Open Market | 948,948 | $1.8M | 4/11/2022 |
| Ali Behbahani | ▲ Buy | Open Market | 2,631,578 | $5.0M | 4/11/2022 |
| New Enterprise Associates 16, L.P. | ▲ Buy | Open Market | 2,631,578 | $5.0M | 4/11/2022 |
| Makhzoumi Mohamad | ▲ Buy | Open Market | 2,631,578 | $5.0M | 4/11/2022 |
| Sonsini Peter W. | ▲ Buy | Open Market | 948,948 | $1.8M | 4/11/2022 |
| Makhzoumi Mohamad | ▲ Buy | Open Market | 948,948 | $1.8M | 4/11/2022 |
| Walker Paul Edward | ▲ Buy | Open Market | 948,948 | $1.8M | 4/11/2022 |
| BASKETT FOREST | ▲ Buy | Open Market | 2,631,578 | $5.0M | 4/11/2022 |
| Edward T. Mathers | ▲ Buy | Grant | 948,948 | $1.8M | 4/11/2022 |
| Ali Behbahani | ▲ Buy | Open Market | 1,851,852 | — | 10/18/2021 |
| Florence Anthony A. Jr. | ▲ Buy | Open Market | 1,851,852 | — | 10/18/2021 |
| Sonsini Peter W. | ▲ Buy | Open Market | 1,851,852 | — | 10/18/2021 |
| New Enterprise Associates 16, L.P. | ▲ Buy | Open Market | 1,851,852 | — | 10/18/2021 |
| BASKETT FOREST | ▲ Buy | Open Market | 1,851,852 | — | 10/18/2021 |
| Carmen Chang | ▲ Buy | Open Market | 1,851,852 | — | 10/18/2021 |
| Makhzoumi Mohamad | ▲ Buy | Open Market | 1,851,852 | — | 10/18/2021 |
| Scott D. Sandell | ▲ Buy | Open Market | 1,851,852 | — | 10/18/2021 |
| Walker Paul Edward | ▲ Buy | Open Market | 1,851,852 | — | 10/18/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
TRVI releases Q2 2026 earnings and makes Raymond James top health list
Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.
TRVI releases Q2 2026 earnings and makes Raymond James top health list. Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.